Journey Medical Co. (NASDAQ:DERM - Get Free Report) CEO Claude Maraoui sold 18,147 shares of Journey Medical stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $5.13, for a total value of $93,094.11. Following the completion of the sale, the chief executive officer now directly owns 2,092,874 shares of the company's stock, valued at approximately $10,736,443.62. This represents a 0.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Claude Maraoui also recently made the following trade(s):
- On Monday, March 3rd, Claude Maraoui sold 23,508 shares of Journey Medical stock. The shares were sold at an average price of $5.19, for a total value of $122,006.52.
Journey Medical Trading Up 1.6 %
Shares of NASDAQ:DERM traded up $0.08 during midday trading on Friday, reaching $5.14. The company's stock had a trading volume of 79,712 shares, compared to its average volume of 94,557. The firm has a market cap of $107.37 million, a price-to-earnings ratio of -5.47 and a beta of 0.96. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 1.81. Journey Medical Co. has a 1 year low of $2.85 and a 1 year high of $6.89. The business has a 50 day moving average price of $4.58 and a 200 day moving average price of $5.08.
Institutional Investors Weigh In On Journey Medical
A number of hedge funds and other institutional investors have recently made changes to their positions in DERM. Cetera Investment Advisers grew its position in shares of Journey Medical by 21.8% in the fourth quarter. Cetera Investment Advisers now owns 13,839 shares of the company's stock valued at $54,000 after purchasing an additional 2,478 shares during the period. Nwam LLC purchased a new stake in Journey Medical during the third quarter valued at about $59,000. Kovitz Investment Group Partners LLC purchased a new stake in Journey Medical during the third quarter valued at about $66,000. Dimensional Fund Advisors LP purchased a new stake in Journey Medical during the fourth quarter valued at about $80,000. Finally, Citadel Advisors LLC purchased a new stake in Journey Medical during the fourth quarter valued at about $174,000. Hedge funds and other institutional investors own 7.25% of the company's stock.
About Journey Medical
(
Get Free Report)
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
See Also
Before you consider Journey Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Journey Medical wasn't on the list.
While Journey Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
